| 영문 | acetylsalicylic acid | 한글 | 아세틸살리실산 |
|---|---|---|---|
| 설명 | 상품명이 아스피린(asprin)인 약. 대표적인 비스테로이드 항염약이다. 즉 항염증(anti-inflammatory), 진통(analgesis), 해열(anti-pyretic)의 효과가 모두 뛰어나지만 위장장애, 과다호흡, 라이증후군(Reye syndrome) 등의 부작용이 있다. |
||
| 영문 | uric acid | 한글 | 요산 |
|---|---|---|---|
| 설명 | 결정성의 산. 2, 6, 8-trioxypurine. 화학식은 C5H4N4O3로 사람과 동물의 오줌에서 얻을 수 있다. 핵의 대사산물의 하나. 물, 알콜, 에테르(ether)에는 거의 녹지 않으나 알칼리염의 용액에는 녹는다. 이것의 나트륨염 형태(sodium urate)가 결석의 대부분을 차지한다. 급성백혈병 치료 초기단계와 통풍(Gout)에서 혈중요산이 급격히 오를 수 있다. |
||
| 영문 | acid-fast bacillus | 한글 | 항산막대균, 항산균 |
|---|---|---|---|
| 설명 | 아닐린 색소에 염색되기 힘드나 일단 염색되면 강산으로 처리하여도 탈색되지 아니하는 세균을 통틀어 이르는 말. 결해균, 나병균 따위가 있다. |
||
| 영문 | acid-fast staining | 한글 | 항산염색 |
|---|---|---|---|
| 설명 | 항산성성질(좀처럼 염색이 되지 않으나 한번 염색이 되면 산성용액에 의해서 탈색이 되지 않는 성질)을 가진 균(예를 들면 결핵균 등)의 검출에 이용되는 염색방법. 방법에는 Ziehl-Neelson법과 Kinyoun법 등이 있다. |
||
| 영문 | nucleic acid | 한글 | 핵산 |
|---|---|---|---|
| 설명 | 염기, 당, 인산으로 이루어진 뉴클레오티드가 긴 사슬 모양으로 중합된 고분자 물질. 유전이나 단백질 합성을 지배하는 중요한 물질로, 생물의 증식을 비롯한 생명 활동 유지에 중요한 작용을 한다. 구성 당인 오탄당이 리보오스인 리보핵산과 디옥시리보오스인 디옥시리보 핵산으로 나뉜다. 펜토스로서 리보스나 데옥시리보스 어느 한쪽만을 포함하며 전자를 리보핵산(RNA), 후자를 데옥시리보핵산(deoxyribonucleic acid, DNA)이라 부른다. 모두 4종류의 유기염기에 의해 특징지어지며 아데닌, 구아닌 및 시토신은 양자에 공통이다. 티민은 DNA에, 우라실은 RNA에 포함된다. DNA는 주로 핵에 존재하며 형질유전에 그리고 RNA는 세포질속에서 단백질 합성에 관여한다. 섭취된 핵산은 소화관에서 구성분자로까지 가수분해되어 흡수된다. |
||
| ESI | elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection |
|---|---|
| PTI | pancreatic trypsin inhibitor; persistent tolerant infection; Pictorial Test of Intelligence; placent... |
| STI | Scientific and Technical Information; serum trypsin inhibitor; soybean trypsin inhibitor; systolic t... |
| AA | abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];... |
| OA | obstructive apnea; occipital artery; occipito-anterior; occiput anterior; octanoic acid; ocular albi... |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
|---|---|
| mammary derived growth inhibitor | Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells. (18 Nov 1997) |
| mechanism-based inhibitor | A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme. Synonym: mechanism-based inhibitor. (05 Mar 2000) |
| glucosidase inhibitor | Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence. (05 Mar 2000) |
| medication, ace-inhibitor | Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart. (12 Dec 1998) |
| residual inhibitor | A sound-generating device, worn in the ear, which inhibits or suppresses the sounds of tinnitus by masking, with a residual inhibitory effect when the device is turned off. (05 Mar 2000) |
| respiratory inhibitor | A compound that inhibits the respiratory chain. Synonym: respiratory poison. (05 Mar 2000) |
| cholinesterase inhibitor | <pharmacology> These are substances which which act to inhibit acetylcholinesterase, the enzyme which breaks down acetylcholine and thus enhance and subsequently prevent transmission of nerve impulses from one nerve cell to another or to a muscle. Examples include pyridostigmine, ambenonium and neostigmine. (15 Jan 1998) |
| monoamine oxidase inhibitor | <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression. Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions. Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine. Acronym: MAOI (26 Mar 1998) |
| complement cytolysis inhibitor | <protein> Vertebrate glycoprotein of uncertain function. Secreted as a 400 amino acid peptide, then cleaved to form two 200 amino acid peptides that are linked by a disulphide bridge. Synonym: complement associated protein, complement cytolysis inhibitor, glycoprotein III. (11 Jan 1998) |
| plasminogen activator inhibitor 1 | <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| plasminogen activator inhibitor 2 | <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| cyclooxygenase inhibitor | <pharmacology> Compounds or agents that combine with cyclooxygenase (prostaglandin-endoperoxide synthase) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (08 Mar 2000) |
| protease inhibitor | A drug that binds to and blocks HIV protease from working, thus preventing the production of new infectious viral articles. (09 Oct 1997) |
| proteinase inhibitor inducing factor | See: PIIF. (18 Nov 1997) |